#EBVPTLD

FDA Grants Priority Review to Tab-cel for EBV+ PTLD After Prior Therapies Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

FDA grants priority review to tabelecleucel for relapsed/refractory EBV+ PTLD, a critical step towards the first approved therapy for this severe posttransplant malignancy. PDUFA date Jan 10, 2026. #EBVPTLD #CellTherapy #FDA #Oncology www.targetedonc.com/view/fda-gra...